Dr Yann-Alexandre Vano joins touchONCOLOGY to discuss the role of personalization of treatment in kidney cancer, and the major findings from the BIONIKK trial investigating nivolumab and ipilimumab as a first-line therapy for patients with kidney cancer. The late-breaking abstract ‘Results from the phase 2 BIOmarker driven trial with Nivolumab (N) and Ipilimumab or VEGFR tyrosine Kinase inhibitor (TKI) in naïve metastatic Kidney cancer (m-ccRCC) patients (pts): the BIONIKK trial’(LBA25) was presented at the Virtual 2020 ESMO Congress in September 2020.
Questions
- In which metastatic kidney cancer patients is nivolumab and ipilimumab indicated as first-line therapy, and what are the limitations of its use? (0:06)
- What were the aims and design of the BIONIKK trial? (2:00)
- What were the major findings of the trial? (3:49)
- What will be the impact of these findings on future personalization of treatment according to tumour molecular characteristics in kidney cancer? (6:06)
- What unanswered questions remain in the use of nivolumab and ipilimumab, and what future studies are planned? (8:30)
Speaker Disclosures: Yann-Alexandre Vano has nothing to disclose in relation to this interview.
Support: Interview and filming supported by Touch Medical Media Ltd. The BIONIKK trial was sponsored by Association pour la Recherche des Thérapeutiques Innovantes en Cancérologie – Bristol Myers Squibb.
Filmed in coverage of the Virtual 2020 ESMO Congress.
